Raltitrexed
Alternative Names: D-1694; ICI-D1694; Tomudex; ZD 1694; ZN-D1694Latest Information Update: 05 Nov 2023
At a glance
- Originator The Institute of Cancer Research
- Developer AstraZeneca; Centre Georges Francois Leclerc; Hospira; National Cancer Institute (France)
- Class Antineoplastics; Quinazolines; Small molecules; Thiophenes
- Mechanism of Action Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Colorectal cancer; Malignant-mesothelioma
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 18 Apr 2018 Centre Georges Francois Leclerc completes a phase II trial in Colorectal cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in France (Intra-arterial) (NCT01348412)
- 21 Jun 2017 Phase-II development for Colorectal cancer in patients with unresectable liver metastases is ongoing in France (Intra-arterial) (NCT01348412)